Life-threatening desquamating rash and hyperammonemia following administration of eculizumab for paroxysmal nocturnal hemoglobinuria

American Journal of Hematology

Volumn 83, Issue 11, 2008, Pages 881-883

  Knoll, Bettina M ^a   Letendre, Louis ^a   Steensma, David P ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; AMMONIA; ANTIBIOTIC AGENT; ANTIHISTAMINIC AGENT; CORTICOSTEROID; ECULIZUMAB; INFUSION FLUID; LACTULOSE;

AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AMMONIA BLOOD LEVEL; BLOOD SAMPLING; CASE REPORT; CONFUSION; DEEP VEIN THROMBOSIS; DERMATITIS; DESQUAMATION; DRUG DOSE INCREASE; FEVER; HEMOLYSIS; HUMAN; HYPERAMMONEMIA; KIDNEY FAILURE; LETTER; LUNG EMBOLISM; MACULOPAPULAR RASH; MALE; MENINGITIS; PAROXYSMAL NOCTURNAL HEMOGLOBINURIA; PRIORITY JOURNAL; PROTEIN RESTRICTION; SKIN BIOPSY; SKIN NECROSIS; SKIN TINGLING; THROMBOSIS; URINALYSIS;

AGED; ANTIBODIES, MONOCLONAL; COMPLEMENT C5; DERMATITIS, EXFOLIATIVE; HEMOGLOBINURIA, PAROXYSMAL; HUMANS; IMMUNOLOGIC FACTORS; MALE;

EID: 55549093797     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.21265     Document Type: Letter

References (5)

1. Brodsky RA, Young NS, Antonioli E, et al. Multicenter phase III study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria. Blood 2007;111:1840-1847.
2. Hillmen P, Hall C, Marsh JC, et al. Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria. N Engl J Med 2004;350:552-559.
3. Hillmen P, Muus P, Duhrsen U, et al. Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria. Blood 2007;110:4123-4128.
4. Hillmen P, Young NS, Schubert J, et al. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med 2006;355:1233-1243.
5. White JM, Smith CH, Robson A, et al. DRESS syndrome caused by efalizumab. Clinical Exp Dermatol 2008;33:50-52.